Haas C, Dendoune F, Persoz M, Le Jeunne C, Hugues F C
Service de Médecine interne, Hôpital Européen Georges Pompidou, 20, rue Leblanc, F 75908 Paris.
Presse Med. 2000 Dec 9;29(38):2092-3.
Even in patients with Behçet's disease, disease, the development of severe aphthosis should suggest the possibility of a drug reaction.
We observed a case of giant lingual aphthosis that developed four months after adding microrandil to the regimen of a patient with Behçet's disease who had been treated with colchicine for 16 years. The aphthosis healed after withdrawal of nicorandil.
There have been 21 cases of nicorandil-induced buccal aphthosis reported in the literature. All healed at drug withdrawal. He delay between initiation of treatment of the stomatitis in most patients, the development of the aphthosis after increasing he nicorandil dose in two patients, its regression after reducing the dose in one and pathology date from biopsied cases suggest a dose-dependent toxic mechanism rather than an immunoallergic process is involved. To our knowledge, our case is the first reported with Behçet's disease. In our opinion, nicorandil should not be given to patients with Behçet's disease.
即使在白塞病患者中,严重口疮性溃疡的出现也应提示药物反应的可能性。
我们观察到1例巨大舌部口疮性溃疡病例,该病例发生在一名接受秋水仙碱治疗16年的白塞病患者加用尼可地尔后4个月。停用尼可地尔后口疮性溃疡愈合。
文献中已报道21例尼可地尔诱发的颊部口疮性溃疡病例。所有病例在停药后均愈合。大多数患者口腔炎治疗开始后出现口疮性溃疡的延迟情况、2例患者增加尼可地尔剂量后出现口疮性溃疡、1例患者减少剂量后口疮性溃疡消退以及活检病例的病理数据提示,其涉及剂量依赖性毒性机制而非免疫过敏过程。据我们所知,我们的病例是首例报道的合并白塞病的病例。我们认为,白塞病患者不应使用尼可地尔。